HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.

Phase 1 Clinical Trials

Phase 1 Clinical Trials

We’re here for you. Call us at 844-346-7222 or

While browsing through our list of open cancer clinical trials, you might notice that some are labeled with phases that graduate from Phase 0 to Phase 4. If you’re interested in participating in a Phase 1 trial but aren’t sure what the process might involve or what to expect, Regional Cancer Care Associates’ quick overview of this type of cancer clinical trial can help you make a more informed, confident decision.

What Are Clinical Trials?

Trials are categorized into phases based on the type of information gathered. For example, Phase 0 studies are typically just for exploratory research, while Phase 4 studies usually look at drugs that have already been approved by the U.S. Food and Drug Administration (FDA). Each study builds on the knowledge gained from previous studies.

Purpose of Phase 1 Studies

In a Phase 1 study, an investigational treatment is given to humans, often for the first time. Extensive research has already been done and the drug has been tested in the laboratory, but now it’s time to see how safe and effective the agent is for humans. The main goal is to determine the impact of a specified drug on the human body and how it interacts with that drug.

In general, Phase 1 studies help researchers figure out the best dosages to give to patients with cancer. In the process, they also help identify any potential side effects of a new drug, although at this phase rare side effects can be more difficult to detect. The results of Phase 1 studies can then be used to get a better understanding of the drug and how doctors can use it to help current and future cancer patients.

How Phase 1 Studies Are Conducted

Phase 1 cancer clinical trials often involve only a small group of people, and it’s common for them to have different types of cancer. Researchers start by administering extremely low doses to patients and then gradually introduce higher doses. There are no placebos (dummy pills) in Phase 1 trials, which means every participant receives the new drug.

Going into Phase 1 cancer clinical trials, some participants may feel apprehensive or fearful. But it’s important to know that these trials are safe and you’ll be closely monitored for side effects the whole time. Plus, the screening process helps verify whether you’d be a good candidate for the trial. If you have any questions, always reach out to your doctor.

Join a Phase 1 Clinical Trial Now

Interested in learning more about cancer clinical trials? If you would like to take part in a trial, RCCA offers a complete list of all available Phase 3 studies. To learn more, review our current list of all clinical trials, contact one of our 30 locations throughout New Jersey, Connecticut, and Maryland or call 201-518-3587 for additional details.

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

67 Clinical Trials
Phase 1 Clinical Trials Phase II Accepting Patients
nct/study# NCT04165798 / MK3475-U01

Master Study: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naïve Patients with Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A) – NCT04165070 KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B) – NCT04165083 KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated with anti-PD-(L)1 Therapy (MK-3475-01C) – NCT04165096 A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Learn More
Phase 1 Clinical Trials Phase I/II Accepting Patients
nct/study# NCT03997968 / CYT-0851-01-REFMAL-639

A Multi-Center, Open Label Phase 1/2 Study Of CYT-0851, An Oral RAD51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors

Learn More
Phase 1 Clinical Trials Phase I Accepting Patients
nct/study# NCT03564691 / MK-4830-001

A Phase 1 Open Label, Multi-Arm, Multicenter Study Of MK-4830 As Monotherapy And In Combination With Pembrolizumab For Participants With Advanced Solid Tumors

Learn More
Phase 1 Clinical Trials Phase I Accepting Patients
nct/study# NCT04612751 / DS1062-A-U104

A Phase 1b, Multicenter, 2-Part, Open-Label Study Of DS-1062a In Combination With Durvalumab In Subjects With Advanced Or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations And Previously Treated With Platinum-Based Chemotherapy With Or Without Prior Immunotherapy

Learn More
Phase 1 Clinical Trials Phase I Accepting Patients
nct/study# NCT02964013 / MK-7684-001

A Phase 1 Trial Of MK-7684 As Monotherapy And In Combination With Pembrolizumab In Subjects With Advanced Solid Tumors

Learn More
Phase 1 Clinical Trials Phase I/II Accepting Patients
nct/study# NCT04145622 / DS7300-A-J101

Phase I/II, Two-Part, Multicenter First-In-Human Study Of DS-7300a In Subjects With Advanced Solid Malignant Tumors

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.